MaxCyte buys gene therapy analytics firm SeQure Dx
30th Jan 2025 13:55
(Alliance News) - MaxCyte Inc on Thursday said it has acquired SeQure Dx Inc, as it looks to improve its gene therapy testing process. Read More
| Price | 355.00p on 05-02-2025 at 15:08:49 |
|---|---|
| Change | 6.00p 1.72% |
| Buy | 358.00p |
| Sell | 352.00p |
| Buy / Sell MXCT Shares | |
| Last Trade: | Sell 3.00 at 353.00p |
| Day's Volume: | 1,838 |
| Last Close: | 349.00p |
| Open: | 349.00p |
| ISIN: | US57777K1060 |
| Day's Range | 349.00p - 355.00p |
| 52wk Range: | 256.00p - 405.00p |
| Market Capitalisation: | £374m |
| VWAP: | 350.36126p |
| Shares in Issue: | 105m |
Sector: Medicine and Biotech
Listed In: FTSE AIM 100, FTSE AIM All-Share,
Recent Trades History MaxCyte (MXCT) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 3 | 353.00p | Ordinary |
15:08:07 - 05-Feb-25 |
| Buy* | 1,500 | 352.00p | Ordinary |
14:54:54 - 05-Feb-25 |
| Sell* | 335 | 343.00p | Ordinary |
08:02:29 - 05-Feb-25 |